The voluntary withdrawal was in response to an FDA request. Eisai said its interpretation of the data differed from the agency's, but the drug's original developer had called off pursuit of European approval when regulators there pointed to potential tumor risk from long-term use.
Ten months in, CEO of Arena Pharmaceuticals Amit Munshi has made some radical changes to the fragmented company, pulling away from its flagship weight loss drug to focus on the clinical pipeline.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.